Loading...
Loading...
Browse all stories on DeepNewz
VisitCHARM Receives Significant Research Grant by End of 2024
NIH • 33%
Gates Foundation • 33%
Wellcome Trust • 34%
Research funding announcements from government agencies or private foundations
MIT and Harvard Develop CHARM, an Epigenetic Gene-Silencing Tool, to Combat Prion Diseases
Jun 27, 2024, 07:38 PM
Researchers from MIT and Harvard, in collaboration with the Broad Institute and Whitehead Institute, have developed a new, powerful gene-silencing tool called CHARM. This epigenetic editor shows promise as a therapy against fatal prion diseases by turning off the disease-causing gene. The compact epigenetic editor is small enough to fit into an adeno-associated virus (AAV), which allows it to permeate throughout the brain and effectively silence prions in mice. Chroma Medicine has licensed CHARM for use outside prion disease, paving the way for a new class of genetic approaches to treat certain diseases.
View original story
Less than $1 million • 33%
$1-5 million • 33%
More than $5 million • 33%
Yes • 50%
No • 50%
NIH • 25%
CDC • 25%
Bill & Melinda Gates Foundation • 25%
Other • 25%
$1 million - $2 million • 33%
$2 million - $5 million • 33%
More than $5 million • 33%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
Yes • 50%
No • 50%
Up to $500 million • 25%
$501 million to $1 billion • 25%
$1.01 billion to $1.5 billion • 25%
Over $1.5 billion • 25%
National Institutes of Health (NIH) • 25%
National Science Foundation (NSF) • 25%
European Research Council (ERC) • 25%
Other • 25%
Yes • 50%
No • 50%
Cancer • 25%
Genetic disorders • 25%
Cardiovascular diseases • 25%
Neurological disorders • 25%